MCID: KRT006
MIFTS: 52

Keratoconjunctivitis malady

Categories: Eye diseases

Aliases & Classifications for Keratoconjunctivitis

Aliases & Descriptions for Keratoconjunctivitis:

Name: Keratoconjunctivitis 12 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9368
ICD10 33 H16.2 H16.20
ICD9CM 35 370.40
MeSH 42 D007637
NCIt 47 C34744
UMLS 69 C0022573

Summaries for Keratoconjunctivitis

MalaCards based summary : Keratoconjunctivitis is related to uveitis and tuberculosis. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Zinc and Cyclosporine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 71 Keratoconjunctivitis is inflammation (\"-itis\") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 337)
id Related Disease Score Top Affiliating Genes
1 uveitis 29.9 CD79A ICAM1 TNF
2 tuberculosis 29.5 IL2 IL4 TNF
3 lagophthalmos 29.4 IL4 TNF
4 rheumatoid arthritis 29.1 CD79A CXCL8 ICAM1 IFNG IL2 IL4
5 vernal keratoconjunctivitis 12.3
6 superior limbic keratoconjunctivitis 12.3
7 keratoconjunctivitis sicca 12.3
8 atopic keratoconjunctivitis 12.1
9 neurotrophic keratoconjunctivitis 11.8
10 punctate epithelial keratoconjunctivitis 11.8
11 shipyard eye 11.5
12 phlyctenulosis 11.4
13 sjogren's syndrome 11.3
14 acute contagious conjunctivitis 11.1
15 exposure keratitis 10.9
16 myelopathy, htlv-1-associated 10.8
17 dry eye syndrome 10.8
18 tropical spastic paraparesis 10.8
19 retrovirus-associated myelopathy 10.8
20 myoglobinuria recurrent 10.3 IFNG IL4
21 choledochal cyst 10.3 IL3 IL5
22 dahlberg borer newcomer syndrome 10.3 IL13 IL5
23 lens-induced iridocyclitis 10.3 IL4 IL5 RNASE3
24 gastroschisis abdominal wall defects, included 10.3 IFNG IL5
25 steatitis 10.3 IL2 TNF
26 anterior dislocation of lens 10.3 CCL11 IL4 RNASE3
27 tubular renal disease-cardiomyopathy syndrome 10.3 IL4 TNF
28 restrictive cardiomyopathy 10.3 IL5 RNASE3
29 bone peripheral neuroepithelioma 10.3 IL13 IL4 IL5
30 isolated klippel-feil syndrome 10.3 IFNG IL4 IL5
31 lactose intolerance 10.3 IL13 IL4 IL5
32 askin's tumor 10.3 IL13 IL4 IL5
33 asymptomatic neurosyphilis 10.3 IFNG IL4
34 duodenal somatostatinoma 10.2 IL13 IL4 IL5
35 peptidic growth factors deficiency 10.2 CCL11 IL5
36 crustacean allergy 10.2 IFNG IL13 IL4
37 heart septal defect 10.2 CD79A RNASE3
38 bile duct signet ring cell carcinoma 10.2 IL5 RNASE3 TNF
39 brown shrimp allergy 10.2 CD79A IL5 RNASE3
40 sarcoma 10.2 IL2 IL4
41 aortic atherosclerosis 10.2 IL13 IL5 TNF
42 coenurosis 10.2 CD79A IL4 IL5
43 isthmus cancer 10.2 CCL11 CD79A IL4
44 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.2 IFNG IL2 TNF
45 gonadal disease 10.2 CD79A IL2 IL4
46 inclusion conjunctivitis 10.2 CD79A IL2 IL5
47 sparganosis 10.2 CD79A ICAM1 IL4
48 parametritis 10.2 IFNG IL2 TNF
49 ectodermal dysplasia bartalos type 10.2 IFNG IL4 TNF
50 cyclosporiasis 10.2 IFNG IL2 TNF

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 IL4 IL5 TNF TSLP AOC1 CCL11
2 homeostasis/metabolism MP:0005376 10.11 AOC1 CD79A ICAM1 IFNG IL13 IL2
3 immune system MP:0005387 10.06 CCL11 CCL17 CD79A ICAM1 IFNG IL13
4 digestive/alimentary MP:0005381 10.03 TNF TSLP ICAM1 IFNG IL13 IL2
5 neoplasm MP:0002006 9.73 CD79A ICAM1 IFNG IL2 IL5 TNF
6 no phenotypic analysis MP:0003012 9.7 CD79A IFNG IL13 IL2 IL4 NGF
7 respiratory system MP:0005388 9.56 CCL11 IFNG IL13 IL2 IL4 IL5
8 vision/eye MP:0005391 9.17 IFNG IL2 IL4 NGF TNF AOC1

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
2
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
3
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
4
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
5
Glycerol Approved, Experimental Phase 4,Phase 2,Phase 3 56-81-5 753
6
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
9
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
10
Ethanol Approved Phase 4 64-17-5 702
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
12
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
13
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
15
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
16
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
17
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
18
Ofloxacin Approved Phase 4 82419-36-1 4583
19
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
20
Menthol Approved Phase 4 2216-51-5 16666
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
22
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
23
Dipivefrin Approved Phase 4 52365-63-6 3105
24
Povidone-iodine Approved Phase 4 25655-41-8
25
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
26
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
27
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
28
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
29
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
30 vitamin d Phase 4
31
Iodine Phase 4 7553-56-2 807
32 cadexomer iodine Phase 4
33 Analgesics Phase 4,Phase 3,Phase 2
34 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
36 Nasal Decongestants Phase 4,Phase 3,Phase 2,Phase 1
37 Ganciclovir triphosphate Phase 4,Phase 2
38 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1
39 Tocopherols Phase 4
40 Tocotrienols Phase 4
41 Nucleic Acid Synthesis Inhibitors Phase 4
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
43 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Trace Elements Phase 4
45 Hormone Antagonists Phase 4,Phase 3,Phase 2
46 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
47 Hormones Phase 4,Phase 3,Phase 2
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
50 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 430)
id Name Status NCT ID Phase
1 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Unknown status NCT01533480 Phase 4
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4
4 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4
5 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4
6 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4
7 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4
8 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4
9 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4
10 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4
11 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4
12 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4
13 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4
14 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4
15 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4
16 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4
17 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
18 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4
19 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4
20 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
21 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
22 TearLab Refractive Surgery Dry Eye Study Completed NCT01176045 Phase 4
23 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
24 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4
25 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
26 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4
27 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4
28 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
29 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
30 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4
31 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
32 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4
33 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4
34 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4
35 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4
36 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4
37 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4
38 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4
39 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4
40 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4
41 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4
42 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4
43 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4
44 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
45 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4
46 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
47 Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Completed NCT00909324 Phase 4
48 Systane Clinical Experience Study Completed NCT00818909 Phase 4
49 Efficacy and Acceptability of Two Lubricant Eye Drops Completed NCT00756678 Phase 4
50 Refractive Surgery and Optive Compatibility Study Completed NCT00469157 Phase 4

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

MalaCards organs/tissues related to Keratoconjunctivitis:

39
Eye, Testes, T Cells, Salivary Gland, Bone, Bone Marrow, Thyroid

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 1070)
id Title Authors Year
1
Molecular phylogeny of a novel human adenovirus type 8 strain causing a prolonged, multi-state keratoconjunctivitis epidemic in Germany. ( 28084428 )
2017
2
Vitamin D levels in children affected by vernal keratoconjunctivitis. ( 27786545 )
2017
3
Herding conditions related to infectious keratoconjunctivitis in semi-domesticated reindeer: a questionnaire-based survey among reindeer herders. ( 27068819 )
2016
4
Notes from the Field: Health Care-Associated Outbreak of Epidemic Keratoconjunctivitis - West Virginia, 2015. ( 27078721 )
2016
5
Epidemic Keratoconjunctivitis-Causing Adenoviruses Induce MUC16 Ectodomain Release To Infect Ocular Surface Epithelial Cells. ( 27303700 )
2016
6
Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27658509 )
2016
7
Very low prevalence of keratoconus in a large series of vernal keratoconjunctivitis patients. ( 27640005 )
2016
8
Superior Limbic Keratoconjunctivitis-like Inflammation in Patients with Chronic Graft-Versus-Host Disease. ( 27179980 )
2016
9
Outcomes of different concentrations of human amniotic fluid in a keratoconjunctivitis sicca-induced mouse model. ( 26767655 )
2016
10
Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models. ( 27791390 )
2016
11
A systematic review and meta-analysis of the antibiotic treatment for infectious bovine keratoconjunctivitis: an update. ( 27427193 )
2016
12
Vernal Keratoconjunctivitis in Kashmir: A temperate zone. ( 26961753 )
2016
13
Quiescent and Active Tear Protein Profiles to Predict Vernal Keratoconjunctivitis Reactivation. ( 26989694 )
2016
14
Allogeneic Mesenchymal Stem Cell Transplantation in Dogs With Keratoconjunctivitis Sicca. ( 28003932 )
2016
15
Clinical Usefulness of Monitoring Expression Levels of CCL24 (Eotaxin-2) mRNA on the Ocular Surface in Patients with Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis. ( 27721987 )
2016
16
Genomic identification of human vaccinia virus keratoconjunctivitis and its importance as a laboratory-acquired infection. ( 27958202 )
2016
17
Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis. ( 26957853 )
2016
18
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27032024 )
2016
19
Unusual course of microsporidial keratoconjunctivitis as an occupational hazard in a veterinary physician. ( 27521681 )
2016
20
The Use of Bandage Contact Lenses in Adenoviral Keratoconjunctivitis. ( 26671622 )
2016
21
Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis. ( 27103784 )
2016
22
An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis. ( 27461427 )
2016
23
Prevalence and associated factors of vernal keratoconjunctivitis among children in Gondar city, Northwest Ethiopia. ( 27681885 )
2016
24
Effect of 0.05% topical cyclosporine for the treatment of symptomatic subepithelial infiltrates due to adenoviral keratoconjunctivitis. ( 27162741 )
2016
25
Carbachol improves the secretion of transplanted submandibular glands during the latent period after microvascular autologous transplantation for severe keratoconjunctivitis sicca. ( 27094607 )
2016
26
Vernal keratoconjunctivitis: culmination of management using immunosuppression, surgical and prosthetic therapy over quarter century. ( 27881591 )
2016
27
Comparison of Efficacy of Two Different Topical 0.05% Cyclosporine A Formulations in the Treatment of Adenoviral Keratoconjunctivitis-Related Subepithelial Infiltrates. ( 27065851 )
2016
28
Selection pressure in the human adenovirus fiber knob drives cell specificity in epidemic keratoconjunctivitis. ( 27512073 )
2016
29
Outbreak of Adenovirus serotype 8 keratoconjunctivitis in Puducherry, South India: a molecular epidemiological study. ( 27131013 )
2016
30
Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. ( 27653428 )
2016
31
Keratoconjunctivitis sicca exacerbation in a dog treated with systemic atenolol. ( 27071733 )
2016
32
Angiographic Evaluation of Inflammation in Atopic Keratoconjunctivitis. ( 27901637 )
2016
33
Serum Vitamin D Levels in Children with Vernal Keratoconjunctivitis. ( 27775457 )
2016
34
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27490054 )
2016
35
Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm. ( 27050351 )
2016
36
Efficacy of Bdellovibrio bacteriovorus 109J for the treatment of dairy calves with experimentally induced infectious bovine keratoconjunctivitis. ( 27580114 )
2016
37
Impact of Vernal Keratoconjunctivitis on School Children in Egypt. ( 27128625 )
2016
38
Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca. ( 26731192 )
2016
39
Age-related spontaneous lacrimal keratoconjunctivitis is accompanied by dysfunctional T regulatory cells. ( 27706128 )
2016
40
Omalizumab Treatment of Vernal Keratoconjunctivitis. ( 26795360 )
2016
41
Erratum to: Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27919262 )
2016
42
Corresponding author's response to letter to the editor on "An adenovirus 4 outbreak amongst staff in a pediatric ward manifesting as keratoconjunctivitis-a possible failure of contact and aerosol infection control". ( 27639756 )
2016
43
Episcleral cyclosporine A implants for the management of unilateral keratoconjunctivitis sicca in an 8-year-old mare. ( 26945681 )
2016
44
Chaperone patterns in vernal keratoconjunctivitis are distinctive of cell and Hsp type and are modified by inflammatory stimuli. ( 26613380 )
2016
45
Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature. ( 27909980 )
2016
46
Atopic keratoconjunctivitis: long-term results of medical treatment and penetrating keratoplasty. ( 28076564 )
2016
47
New Finding in Vernal Keratoconjunctivitis: Splendore-Hoeppli Phenomenon. ( 27027918 )
2016
48
Genetic variability of human adenovirus type 8 causing epidemic and sporadic cases of keratoconjunctivitis. ( 26957298 )
2016
49
Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis. ( 27310883 )
2016
50
The Study of Interleukin-17 Level in Vernal Keratoconjunctivitis Disease and its Relationship between Symptom and Sign Severity. ( 27420560 )
2016

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 AOC1 CCL11 CD79A CXCL8 ICAM1 IFNG
2
Show member pathways
13.86 CCL11 CCL17 CXCL8 IL13 IL2 IL3
3
Show member pathways
13.7 CCL11 CCL17 CXCL8 IFNG IL13 IL2
4
Show member pathways
13.56 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
5
Show member pathways
13.46 CCL11 CCL17 CXCL8 IL13 IL2 IL3
6
Show member pathways
13.41 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
7
Show member pathways
13.35 CCL11 CCL17 CXCL8 IL13 IL2 IL3
8
Show member pathways
12.86 CXCL8 ICAM1 IFNG IL13 IL2 IL4
9
Show member pathways
12.74 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
10
Show member pathways
12.67 IFNG IL13 IL2 IL4 IL5 TNF
11
Show member pathways
12.66 CD79A IFNG IL2 IL4 TNF
12
Show member pathways
12.66 CD79A IL13 IL3 IL4 IL5 TNF
13 12.61 CD79A IFNG IL2 IL3 IL4 TNF
14
Show member pathways
12.59 ICAM1 IFNG IL2 IL3 IL4 TNF
15
Show member pathways
12.49 IFNG IL2 IL4 IL5 TNF
16
Show member pathways
12.41 CCL11 CCL17 CXCL8 IFNG IL13 IL4
17
Show member pathways
12.4 ICAM1 IFNG IL2 IL4 TNF
18
Show member pathways
12.32 IFNG IL13 IL2 IL3 IL4 IL5
19
Show member pathways
12.27 CCL11 CXCL8 IFNG IL4 TNF
20 12.21 CXCL8 IL13 NGF TNF
21
Show member pathways
12.13 CXCL8 IFNG IL13 IL2 IL3 IL4
22 12.12 CXCL8 ICAM1 IFNG IL2 IL4 TNF
23 12.11 CD79A IFNG IL2 IL3 IL4 IL5
24 12.09 CCL11 CXCL8 ICAM1 IL13 IL4 TNF
25 11.96 IL3 IL4 IL5 TNF
26
Show member pathways
11.95 IFNG IL2 IL4
27
Show member pathways
11.93 IFNG IL2 TNF
28 11.93 CXCL8 ICAM1 IFNG TNF
29 11.92 CXCL8 IFNG IL3
30 11.91 CXCL8 ICAM1 IFNG IL13 IL2 IL4
31 11.89 CXCL8 ICAM1 TNF
32 11.88 IFNG IL13 IL2 IL4 IL5 TNF
33 11.87 CXCL8 IFNG TNF
34 11.87 CXCL8 ICAM1 TNF
35 11.81 ICAM1 IL4 IL5 TNF
36
Show member pathways
11.8 CXCL8 ICAM1 IFNG IL2 TNF
37 11.79 CCL11 CXCL8 IL13 IL4 IL5 TNF
38
Show member pathways
11.79 CXCL8 IFNG IL2 IL3 IL4 IL5
39 11.77 IFNG IL2 TNF
40 11.76 CCL11 CCL17 IL4 IL5
41 11.71 IFNG IL2 IL3
42
Show member pathways
11.67 IFNG IL2 TNF
43 11.66 CXCL8 ICAM1 IL13 IL4 TNF
44 11.63 CXCL8 ICAM1 IFNG TNF
45 11.59 IFNG IL2 TNF
46 11.56 IFNG IL2 TNF
47 11.51 CXCL8 ICAM1 IFNG
48
Show member pathways
11.47 IFNG IL2 TNF
49 11.44 IFNG IL2 IL4 IL5
50 11.4 ICAM1 IFNG TNF

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 AOC1 CCL11 CCL17 CXCL8 IFNG IL13
2 external side of plasma membrane GO:0009897 9.63 CD79A ICAM1 IFNG IL13 IL4 TNF
3 extracellular space GO:0005615 9.47 AOC1 CCL11 CCL17 CXCL8 ICAM1 IFNG

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 44)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.99 AOC1 ICAM1 IFNG IL4
2 MAPK cascade GO:0000165 9.97 IL2 IL3 IL5 TNF
3 cell-cell signaling GO:0007267 9.96 CCL17 IL13 IL2 IL3 NGF
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 CCL11 CCL17 ICAM1 TNF
5 chemotaxis GO:0006935 9.93 CCL11 CCL17 CXCL8 IL4
6 positive regulation of protein phosphorylation GO:0001934 9.91 IFNG IL2 IL4 TNF
7 inflammatory response GO:0006954 9.88 CCL11 CCL17 CXCL8 IL13 IL5 TNF
8 response to virus GO:0009615 9.87 CCL11 IFNG TNF
9 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.86 IL4 IL5 TNF
10 cellular response to lipopolysaccharide GO:0071222 9.85 CXCL8 ICAM1 IFNG TNF
11 movement of cell or subcellular component GO:0006928 9.84 CXCL8 IFNG IL13
12 response to ethanol GO:0045471 9.84 ICAM1 IL13 IL2 IL4
13 chemokine-mediated signaling pathway GO:0070098 9.83 CCL11 CCL17 CXCL8
14 cellular response to tumor necrosis factor GO:0071356 9.83 CCL11 CCL17 CXCL8 ICAM1
15 positive regulation of T cell proliferation GO:0042102 9.82 IFNG IL2 IL4
16 cellular response to interferon-gamma GO:0071346 9.81 CCL11 CCL17 ICAM1
17 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 ICAM1 IL3 IL4 IL5
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 ICAM1 IFNG TNF
19 cellular response to interleukin-1 GO:0071347 9.73 CCL11 CCL17 CXCL8 ICAM1
20 negative regulation of growth of symbiont in host GO:0044130 9.69 IFNG TNF
21 negative regulation of endothelial cell apoptotic process GO:2000352 9.69 ICAM1 IL13 IL4
22 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 IFNG TNF
23 microglial cell activation GO:0001774 9.68 IL13 IL4
24 positive regulation of podosome assembly GO:0071803 9.68 IL5 TNF
25 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL2 IL5
26 neutrophil chemotaxis GO:0030593 9.67 CCL11 CCL17 CXCL8 IFNG
27 positive regulation of mast cell degranulation GO:0043306 9.66 IL13 IL4
28 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IFNG IL4
29 positive regulation of immunoglobulin production GO:0002639 9.64 IL13 IL4
30 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.63 IL2 IL3 IL4
31 regulation of proton transport GO:0010155 9.62 IL13 IL4
32 negative regulation of T-helper 17 cell differentiation GO:2000320 9.62 IL2 IL4
33 positive regulation of mononuclear cell migration GO:0071677 9.61 IL4 TNF
34 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.59 ICAM1 TNF
35 negative regulation of complement-dependent cytotoxicity GO:1903660 9.58 IL13 IL4
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IFNG TNF
37 positive regulation of chemokine biosynthetic process GO:0045080 9.5 IFNG IL4 TNF
38 positive regulation of vitamin D biosynthetic process GO:0060557 9.49 IFNG TNF
39 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 IFNG IL2 IL3 IL4
40 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 IFNG IL2 IL4
41 immune response GO:0006955 9.32 CCL11 CCL17 CXCL8 IFNG IL13 IL2
42 positive regulation of B cell proliferation GO:0030890 9.26 IL13 IL2 IL4 IL5
43 positive regulation of cell proliferation GO:0008284 10.05 IFNG IL2 IL3 IL4 IL5
44 positive regulation of GTPase activity GO:0043547 10.04 CCL11 CCL17 ICAM1 IL2 IL3 IL5

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 CCL11 CCL17 CXCL8 IFNG IL13 IL2
2 growth factor activity GO:0008083 9.35 IL2 IL3 IL4 IL5 NGF
3 chemokine activity GO:0008009 9.33 CCL11 CCL17 CXCL8

Sources for Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....